TrialDiabetes, obesity & metabolism2017

Adding fast-acting insulin aspart to basal insulin significantly improved glycaemic control in patients with type 2 diabetes: A randomized, 18-week, open-label, phase 3 trial (onset 3).

Helena W Rodbard et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.